

## Author Index (Vol. 93)

- Alberti, K.G.M., see Winocour, P.H. (93) 71  
 Aliev, G., see Cirillo, R. (93) 133  
 Anderson, D.C., see Winocour, P.H. (93) 83  
 Angelini, G.D., see Francis, S.E. (93) 155  
 Archbold, P., see Murphy, B.G. (93) 53  
 Arrol, S., see Tames, F.J. (93) 237  
 Arrol, S., see Winocour, P.H. (93) 83  
 Aviram, M., see Hoffman, R. (93) 105
- Balanya, J., see Vilella, E. (93) 145  
 Barcew-Wiszniewska, B., see Wójcicki, J. (93) 7  
 Bernini, F., see Corsini, A. (93) 95  
 Bhatnagar, D., see Winocour, P.H. (93) 83  
 Bihari-Varga, M., see Landi, A. (93) 17  
 Blache, D., Bouthillier, D. and Davignon, J.  
     Acute influence of smoking on platelet behaviour,  
     endothelium and plasma lipids and normalization by Aspirin  
     (93) 179  
 Blann, A.D. and McCollum, C.N.  
     Hemostatic risk factors in patients with vascular disease (93)  
     255  
 Bogers, A.J.J., see Slomp, J. (93) 25  
 Bosman, F., see Span, A.H.M. (93) 41  
 Bouthillier, D., see Blache, D. (93) 179  
 Brook, G.J., see Hoffman, R. (93) 105  
 Bruggemen, C.A., see Span, A.H.M. (93) 41  
 Bueno, M., see Sarria, A. (93) 157
- Capdevila, C., see Gabaldón, M. (93) 217  
 Catapano, A.L., see Corsini, A. (93) 95  
 Cercek, B., see Khorsandi, M. (93) 115  
 Cirillo, R., Aliev, G., Italiano, G. and Prosdoci, M.  
     Functional responses of hindlimb circulation in aged normal  
     and WHHL rabbits (93) 133  
 Clifton, P.M., Wight, M.B. and Nestel, P.J.  
     Is fat restriction needed with HMGCoA reductase inhibitor  
     treatment? (93) 59  
 Corsini, A., Mazzotti, M., Villa, A., Maggi, F.M., Bernini, F.,  
     Romano, L., Romano, C., Fumagalli, R. and Catapano, A.L.  
     Ability of the LDL receptor from several animal species to  
     recognize the human apo B binding domain: studies with LDL  
     from familial defective apo B-100 (93) 95  
 Craig, W.Y. and Ledue, T.B.  
     The effect of long term storage on serum Lp(a) levels (93) 261
- Daerr, W.H., Windler, E.T.E and Greten, H.  
     Streptavidin binds to a 130-kDa protein from solubilized  
     human skin fibroblast and Hep G 2 cell membranes (93) 161  
 Davignon, J., see Blache, D. (93) 179
- de Reeder, E.G., see Slomp, J. (93) 25  
 Duly, E., see Murphy, B.G. (93) 53  
 Durrington, P.N., see Tames, F.J. (93) 237  
 Durrington, P.N., see Winocour, P.H. (93) 83  
 Dutkiewicz, T., see Wójcicki, J. (93) 7
- Ernst, E.  
     Oral contraceptives, fibrinogen and cardiovascular risk (93) 1
- Fagin, J.A., see Khorsandi, M. (93) 115  
 Fishbein, M.C., see Khorsandi, M. (93) 115  
 Fleta, J., see Sarria, A. (93) 157  
 Forrester, J.S., see Khorsandi, M. (93) 115  
 Francis, S.E., Holt, C.M., Taylor, T., Gadsdon, P. and Angelini,  
     G.D.  
     Heparin and neointimal thickening in an organ culture of  
     human saphenous vein (93) 155  
 Fukazaki, H., see Tsunemitsu, M. (93) 229  
 Fumagalli, R., see Corsini, A. (93) 95
- Gabaldón, M., Capdevila, C. and Zúñiga, A.  
     Effect of spontaneous pathology and thrombin on leukocyte  
     adhesion to rat aortic endothelium (93) 217  
 Gadsdon, P., see Francis, S.E. (93) 155  
 Giełdanowski, J., see Wójcicki, J. (93) 7  
 Giner, A., see Sarria, A. (93) 157  
 Gittenberger-de Groot, A.C., see Slomp, J. (93) 25  
 Gonet, B., see Wójcicki, J. (93) 7  
 Goto, K., see Miyauchi, T. (93) 257  
 Gotoda, T., see Inoue, I. (93) 245  
 Grauls, G., see Span, A.H.M. (93) 41  
 Greten, H., see Daerr, W.H. (93) 161  
 Gruber, E., see Landi, A. (93) 17
- Harada, K., see Inoue, I. (93) 245  
 Harland, J.O.E., see Winocour, P.H. (93) 71  
 Henry, W., see Murphy, B.G. (93) 53  
 Hoffman, R., Brook, G.J. and Aviram, M.  
     Hypolipidemic drugs reduce lipoprotein susceptibility to  
     undergo lipid peroxidation: in vitro and ex vivo studies (93)  
     105  
 Holl, L.G., see Tribble, D.L. (93) 189  
 Holt, C.M., see Francis, S.E. (93) 155
- Inaba, T., see Inoue, I. (93) 245  
 Inoue, I., Inaba, T., Motoyoshi, K., Harada, K., Shimano, H.,  
     Kawamura, M., Gotoda, T., Oka, T., Shiomi, M., Watanabe,  
     Y., Tsukada, T., Yazaki, Y., Takaku, F. and Yamada, N.  
     Macrophage colony stimulating factor prevents the progres-

- sion of atherosclerosis in Watanabe heritable hyperlipidemic rabbits (93) 245
- Ishikawa, Y., see Tsunemitsu, M. (93) 229
- Ishola, M., see Winocour, P.H. (93) 83
- Italiano, G., see Cirillo, R. (93) 133
- Juzwiak, S., see Wójcicki, J. (93) 7
- Kadłubowska, D., see Wójcicki, J. (93) 7
- Kawamura, M., see Inoue, I. (93) 245
- Keller, L., see Landi, A. (93) 17
- Khorsandi, M., Fagin, J.A., Fishbein, M.C., Forrester, J.S. and Cercek, B.  
Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats (93) 115
- Kotze, M.J., see Kriek, J.A. (93) 165
- Krauss, R.M., see Tribble, D.L. (93) 189
- Kriek, J.A., Steyn, K., Weight, M.J., Kotze, M.J. and van Zyl, L.J.  
Response to treatment with simvastatin in a compound FH heterozygote (93) 165
- Kuhn, H., see Roux, S.P. (93) 123
- La Ville, A.E., see Vilella, E. (93) 145
- Laing, I., see Tames, F.J. (93) 237
- Laker, M.F., see Winocour, P.H. (93) 71
- Landi, A., Bihari-Varga, M., Keller, L., Mezey, Z. and Gruber, E.  
Elastase-type enzymes and their relation to blood lipids in atherosclerotic patients (93) 17
- Larraz, L., see Sarria, A. (93) 157
- Lasierra, M.P., see Sarria, A. (93) 157
- Ledue, T.B., see Craig, W.Y. (93) 261
- Lengsfeld, H., see Roux, S.P. (93) 123
- Lutton, C., see Ouguerram, K. (93) 201
- Mackness, M., see Winocour, P.H. (93) 83
- Mackness, M.I., see Tames, F.J. (93) 237
- Maggi, F.M., see Corsini, A. (93) 95
- Magot, T., see Ouguerram, K. (93) 201
- Marsal, S., see Vilella, E. (93) 145
- Masaki, T., see Miyauchi, T. (93) 257
- Masana, L.I., see Vilella, E. (93) 145
- Matsuda, M., see Miyauchi, T. (93) 257
- Mazzotti, M., see Corsini, A. (93) 95
- McCollum, C.N., see Blann, A.D. (93) 255
- McNamee, P., see Murphy, B.G. (93) 53
- Mezey, Z., see Landi, A. (93) 17
- Millar, J.P., see Winocour, P.H. (93) 71
- Miyauchi, T., Sugishita, Y., Matsuda, M., Sakai, H., Suzuki, N., Masaki, T. and Goto, K.  
Increased plasma concentration of endothelin-1 in cholesterol-fed rats (93) 257
- Morand, O.H., see Roux, S.P. (93) 123
- Moreno, L., see Sarria, A. (93) 157
- Motoyoshi, K., see Inoue, I. (93) 245
- Mukhin, D.N. and Prokazova, N.V.  
Neutral glycosphingolipid content and composition of cells from normal and atherosclerotic human aorta (93) 173
- Murphy, B.G., McNamee, P., Duly, E., Henry, W., Archbold, P. and Trinick, T.  
Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis (93) 53
- Nestel, P.J., see Clifton, P.M. (93) 59
- Oka, T., see Inoue, I. (93) 245
- Ouguerram, K., Magot, T. and Lutton, C.  
Metabolism of intestinal triglyceride-rich lipoproteins in the genetically hypercholesterolemic rat (RICO) (93) 201
- Poelmann, R.E., see Slomp, J. (93) 25
- Prokazova, N.V., see Mukhin, D.N. (93) 173
- Prosdoci, M., see Cirillo, R. (93) 133
- Roda, L., see Sarria, A. (93) 157
- Romano, C., see Corsini, A. (93) 95
- Romano, L., see Corsini, A. (93) 95
- Roth, I., see Seifert, P.S. (93) 209
- Roux, S.P., Kuhn, H., Lengsfeld, H. and Morand, O.H.  
Effects of chronic aortic coarctation on atherosclerosis and arterial lipid accumulation in the Watanabe hereditary hyperlipidemic (WHHL) rabbit (93) 123
- Rózewicka, L., see Wójcicki, J. (93) 7
- Sakai, H., see Miyauchi, T. (93) 257
- Samochoń, L., see Wójcicki, J. (93) 7
- Sarria, A., Moreno, L., Fleta, J., Lasierra, M.P., Roda, L., Giner, A., Larraz, L. and Bueno, M.  
Immunoglobulins, complement components and lymphocyte subsets are related to plasma lipoproteins in healthy children (93) 157
- Seifert, P.S., Roth, I. and Zioncheck, T.F.  
The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation (93) 209
- Shimano, H., see Inoue, I. (93) 245
- Shiomi, M., see Inoue, I. (93) 245
- Simons, L.A.  
Dietary fish oils and Lp(a) (93) 169
- Slomp, J., van Munsteren, J.C., Poelmann, R.E., de Reeder, E.G., Bogers, A.J.J.C. and Gittenberger-de Groot, A.C.  
Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening. An immunohistochemical study of changes in extracellular matrix components (93) 25
- Span, A.H.M., Grauls, G., Bosman, F., van Boven, C.P.A. and Bruggeman, C.A.  
Cytomegalovirus infection induces vascular injury in the rat (93) 41
- Steyn, K., see Kriek, J.A. (93) 165
- Sugishita, Y., see Miyauchi, T. (93) 257
- Suzuki, N., see Miyauchi, T. (93) 257
- Takaku, F., see Inoue, I. (93) 245
- Tames, F.J., Mackness, M.I., Arrol, S., Laing, I. and Durrington, P.N.

- Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects (93) 237
- Taniguchi, T., see Tsunemitsu, M. (93) 229
- Taylor, T., see Francis, S.E. (93) 155
- Torbus-Lisiecka, B., see Wójcicki, J. (93) 7
- Tribble, D.L., Holl, L.G., Wood, P.D. and Krauss, R.M.  
Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size (93) 189
- Trinick, T., see Murphy, B.G. (93) 53
- Tsukada, T., see Inoue, I. (93) 245
- Tsunemitsu, M., Ishikawa, Y., Taniguchi, T., Fukazaki, H. and Yokoyama, M.  
Association of N-glycosylation of apolipoprotein B-100 with plasma cholesterol levels in Watanabe heritable hyperlipidemic rabbits (93) 229
- Turner, P.R., see Vilella, E. (93) 145
- van Boven, C.P.A., see Span, A.H.M. (93) 41
- van Munsteren, J.C., see Slomp, J. (93) 25
- Van Zyl, L.J., see Kriek, J.A. (93) 165
- Vilella, E., Balanyà, J., Masana, Ll., Marsal, S., La Ville, A.E. and Turner, P.R.  
Low density lipoprotein ligand-receptor interactions in normal healthy individuals characterized by their *Xba*I apolipoprotein B DNA polymorphism (93) 145
- Villa, A., see Corsini, A. (93) 95
- Watanabe, Y., see Inoue, I. (93) 245
- Weight, M.J., see Kriek, J.A. (93) 165
- Wesołowska, T., see Wójcicki, J. (93) 7
- Wight, M.B., see Clifton, P.M. (93) 59
- Windler, E.T.E., see Daerr, W.H. (93) 161
- Winocour, P.H., Durrington, P.N., Bhatnagar, D., Ishola, M., Mackness, M., Arrol, S. and Anderson, D.C.  
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia (93) 83
- Winocour, P.H., Harland, J.O.E., Millar, J.P., Laker, M.F. and Alberti, K.G.M.M.  
Microalbuminuria and associated cardiovascular risk factors in the community (93) 71
- Wira, D., see Wójcicki, J. (93) 7
- Wójcicki, J., Dutkiewicz, T., Giełdanowski, J., Samochowiec, L., Barcew-Wiszniewska, B., Rózewicka, L., Wira, D., Wesołowska, T., Torbus-Lisiecka, B., Gonet, B., Juzwiak, S. and Kadłubowska, D.  
Essential phospholipids modify immunological functions and reduce experimental atherosclerosis in rabbits (93) 7
- Wood, P.D., see Tribble, D.L. (93) 189
- Yamada, N., see Inoue, I. (93) 245
- Yazaki, Y., see Inoue, I. (93) 245
- Yokoyama, M., see Tsunemitsu, M. (93) 229
- Zioncheck, T.F., see Seifert, P.S. (93) 209
- Zúñiga, A., see Gabaldón, M. (93) 217



## Subject Index (Vol. 93)

- Afrikaner, (93) 165  
Adherence, (93) 41  
Aggregation, (93) 179  
Anti-oxidants, (93) 105  
Aortic endothelium, (93) 217  
Apolipoprotein(a), (93) 53  
Apolipoprotein B, (93) 237  
Apolipoprotein B-100, (93) 95; (93) 229  
Argyrophilic cells, (93) 217  
Arterial wall injury, (93) 115  
Aspirin, (93) 179  
Atherosclerosis, (93) 41; (93) 105; (93) 123; (93) 133; (93) 157; (93) 173; (93) 209; (93) 257  
  
Bezafibrate, (93) 83; (93) 105  
Binding, (93) 145  
Biotinylated lipoproteins, (93) 161  
Blood lipids, (93) 17  
Bradykinin, (93) 133  
  
Cardiovascular disease, (93) 71  
Cardiovascular risk, (93) 1  
Cholesterol metabolism, (93) 201  
Cholesterol, (93) 53; (93) 59; (93) 123; (93) 145; (93) 229  
Cholesterol-fed rats, (93) 257  
Cholesteryl ester, (93) 201  
Cholestyramine, (93) 105  
Chylomicrons, (93) 201  
Cigarette smoking, (93) 179  
Coagulation, (93) 1  
Complement, (93) 157  
Continuous ambulatory peritoneal dialysis (CAPD), (93) 53  
Cytokine, (93) 245  
Cytomegalovirus, (93) 41  
  
Degradation, (93) 145  
Density gradient ultracentrifugation, (93) 189  
Diabetes, (93) 71  
Diabetes mellitus, (93) 237  
Diet, (93) 59  
Ductus arteriosus, (93) 25  
  
Elastase inhibitors, (93) 17  
Elderly, (93) 71  
Endothelin-1, (93) 257  
Endothelium, (93) 41; (93) 179  
Essential phospholipids, (93) 7  
Experimental atherosclerosis, (93) 7  
Extracellular matrix components, (93) 25  
  
Familial hypercholesterolemia, (93) 165; (93) 237  
Fibrinogen, (93) 1; (93) 71  
Fish oils, (93) 169  
Foam cell, (93) 245  
Free cholesterol, (93) 189  
  
Glycation, (93) 237  
Glycosaminoglycans, (93) 25  
Glycosphingolipids, (93) 173  
Gradient gel electrophoresis, (93) 189  
  
HDL, (93) 59  
Healthy, (93) 157  
Hemorheology, (93) 1  
Heparin, (93) 155  
High-fat diet, (93) 7  
Hindlimb circulation, (93) 133  
Hormones, (93) 1  
Human aorta, (93) 173  
Hypercholesterolemia, (93) 83; (93) 95; (93) 105; (93) 123; (93) 201  
Hypertension, (93) 71; (93) 123  
Hypertriglyceridemia, (93) 83; (93) 169  
Hypophysectomy, (93) 115  
  
Immune system, (93) 7  
Immunoassay, (93) 261  
Immunoglobulins, (93) 157  
Inflammation, (93) 209  
Insulin-like growth factor-I, (93) 115  
Intima cells, (93) 173  
Intimal thickening, (93) 25  
Ischemic vascular disease, (93) 17  
  
Kilham rat virus, (93) 217  
  
LDL, (93) 59  
LDL- (B/E) receptor, (93) 161  
LDLR genes, (93) 165  
Leukocyte adhesion, (93) 217  
Ligand blotting, (93) 161  
Lipid, (93) 209  
Lipid accumulation, (93) 41; (93) 173  
Lipid metabolism, (93) 7  
Lipid peroxidation (93) 189  
Lipoprotein(a), (93) 53; (93) 169; (93) 261  
Lipoprotein composition, (93) 83  
Lipoprotein oxidation, (93) 105  
Lipoproteins, (93) 71  
Lipoproteins, (93) 157

Low-density lipoprotein subfractions, (93) 189  
Low-density lipoprotein, (93) 237  
Lymph, (93) 201  
Lymphocyte subsets, (93) 157

M-CSF, (93) 245  
Macrophage, (93) 245  
Microalbuminuria, (93) 71  
Monoclonal antibodies, (93) 95  
*Mycoplasma pulmonis*, (93) 217  
Myocardial infarction, (93) 17

N-glycosylation, (93) 229  
N-linked sugar chain, (93) 229  
Neointimal proliferation, (93) 115

Oral contraceptives, (93) 1  
Organ culture, (93) 155

Persistent ductus arteriosus, (93) 25  
Phospholipids, (93) 123  
Plasma concentration, (93) 257  
Plasma lipids, (93) 179  
Platelet function, (93) 179  
Pravastatin, (93) 105

Rabbit, (93) 7  
Rat, (93) 201  
Restriction fragments, (93) 145  
Risk factors, (93) 255

Sendai virus, (93) 217  
Saphenous vein, (93) 155  
Scanning and transmission electron microscopy, (93) 133  
Serum elastase-type proteases, (93) 17  
Simvastatin, (93) 59; (93) 165  
Storage, (93) 261  
Streptavidin, (93) 161

TBARS, (93) 189  
Thrombin, (93) 217  
Type 1 diabetes, (93) 83

Vascular disease, (93) 255  
Very low density lipoproteins, (93) 201  
von Willebrand factor antigen, (93) 255

Watanabe heritable hyperlipidemic (WHHL) rabbit, (93) 229; (93) 123; (93) 133; (93) 245

